Response rates for FCM and R-FCM (intention-to-treat analysis)
. | FCM . | R-FCM . |
|---|---|---|
| No. of evaluable patients | 62 | 66 |
| CR, no. (%) | 8 (13) | 22 (33) |
| PR, no. (%) | 28 (45) | 30 (45) |
| MR, no. (%) | 4 (6) | 1 (2) |
| SD, no. (%) | 3 (5) | 3 (5) |
| PD, no. (%) | 16 (26) | 8 (12) |
| EX, no. (%) | 3 (5) | 2 (3) |
| CR+PR, no. (%) | 36 (58) | 52 (79) |
. | FCM . | R-FCM . |
|---|---|---|
| No. of evaluable patients | 62 | 66 |
| CR, no. (%) | 8 (13) | 22 (33) |
| PR, no. (%) | 28 (45) | 30 (45) |
| MR, no. (%) | 4 (6) | 1 (2) |
| SD, no. (%) | 3 (5) | 3 (5) |
| PD, no. (%) | 16 (26) | 8 (12) |
| EX, no. (%) | 3 (5) | 2 (3) |
| CR+PR, no. (%) | 36 (58) | 52 (79) |
R-FCM revealed a significantly higher overall response (CR and PR) of 79% versus 58% for FCM (P = .01) and a significantly higher CR rate of 33% versus 13% (P = .005).
CR indicates complete remission; PR, partial remission; MR, minor response; SD, stable disease; PD, progressive disease; and EX, death.